CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Pembrolizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02964559
NCT02964559Phase 2Completed
CompareCT.gov

A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma

Emory University·interventional·Posted Nov 16, 2016·Updated Jun 26, 2024

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab for Recurrent Skin Carcinoma and Skin Squamous Cell Carcinoma. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This phase II trial studies how well pembrolizumab works in treating patients with skin cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 16, 2016
Enrollment StartJan 27, 2017
Primary CompletionMay 18, 2021
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.6 years ago

Interventions

Pembrolizumabbiological

Given IV